Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

Resveratrol inhibits interleukin 1beta-mediated inducible nitric oxide synthase expression in articular chondrocytes by activating SIRT1 and thereby suppressing nuclear factor-kappaB activity.

Authors: Lei, M  Wang, JG  Xiao, DM  Fan, M  Wang, DP  Xiong, JY  Chen, Y  Ding, Y  Liu, SL 
Citation: Lei M, etal., Eur J Pharmacol. 2012 Jan 15;674(2-3):73-9. doi: 10.1016/j.ejphar.2011.10.015. Epub 2011 Oct 25.
Pubmed: (View Article at PubMed) PMID:22044919
DOI: Full-text: DOI:10.1016/j.ejphar.2011.10.015

In chondrocytes, resveratrol, a natural SIRT1 activator, exerts an anti-inflammatory response via inhibition of nuclear factor kappaB (NF-kappaB). Given that SIRT1 inhibits the transactivation potential of NF-kappaB by deacetylating acetylated lysines in p65, the NF-kappaB subunit, we investigated the effects of resveratrol-activated SIRT1 on articular chondrocytes. We found that when chondrocytes were stimulated with interleukin 1beta (IL-1beta), the time- and dose-dependent expression of inducible nitric oxide synthase (iNOS) expression and nitric oxide (NO) production was suppressed by resveratrol. Resveratrol-activated SIRT1 mediated this suppression. SIRT1 suppressed not only the nuclear translocation of NF-kappaB but also the acetylation of p65. Furthermore, acetylated Lys310 in p65, which must be present for transactivation activity, was the immediate downstream target of SIRT1. Therefore, SIRT1 protects against the inflammatory response induced by IL-1beta in articular chondrocytes. Resveratrol, as an activator of SIRT1, merits consideration as a therapeutic agent in the treatment and prevention of osteoarthritis.


Gene Ontology Annotations
Objects Annotated

Additional Information

CRRD Object Information
CRRD ID: 10047123
Created: 2015-07-10
Species: All species
Last Modified: 2015-07-10
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.